The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review
| Autor: | Michele Aieta, Ilaria Ascione, Sabino De Placido, Livio Puglia, Gaetano Facchini, Michele Caraglia, Carlo Buonerba, Matteo Ferro, Guru Sonpavde, Davide Bosso, Giuseppe Di Lorenzo, Giuseppe Lucarelli, Martina Pagliuca, Daniela Terracciano, Sabrina Rossetti, Ottavio De Cobelli, Piero Pignataro |
|---|---|
| Přispěvatelé: | DI LORENZO, Giuseppe, De Placido, Sabino, Pagliuca, Martina, Ferro, Matteo, Lucarelli, Giuseppe, Rossetti, Sabrina, Bosso, Davide, Puglia, Livio, Pignataro, Piero, Ascione, Ilaria, De Cobelli, Ottavio, Caraglia, Michele, Aieta, Michele, Terracciano, Daniela, Facchini, Gaetano, Buonerba, Carlo, Sonpavde, Guru, DE PLACIDO, Sabino |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Bevacizumab medicine.drug_class medicine.medical_treatment Clinical Biochemistry bevacizumab Pharmacology urologic and male genital diseases Monoclonal antibody Targeted therapy 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Interferon Renal cell carcinoma Drug Discovery Medicine monoclonal antibodie PI3K/AKT/mTOR pathway nivolumab business.industry Drug Discovery3003 Pharmaceutical Science targeted therapy medicine.disease Kidney neoplasm Vascular endothelial growth factor 030104 developmental biology chemistry 030220 oncology & carcinogenesis Cancer research Nivolumab business medicine.drug |
| Zdroj: | Expert Opinion on Biological Therapy. 16:1387-1401 |
| ISSN: | 1744-7682 1471-2598 |
| DOI: | 10.1080/14712598.2016.1216964 |
| Popis: | Introduction: While the majority of the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) inhibitors currently used for the therapy of metastatic renal cell carcinoma (mRCC) are small molecule agents inhibiting multiple targets, monoclonal antibodies are inhibitors of specific targets, which may decrease off-target effects while preserving on-target activity. A few monoclonal antibodies have already been approved for mRCC (bevacizumab, nivolumab), while many others may play an important role in the therapeutic scenario of mRCC. Areas covered: This review describes emerging monoclonal antibodies for treating RCC. Currently, bevacizumab, a VEGF monoclonal antibody, is approved in combination with interferon for the therapy of metastatic RCC, while nivolumab, a Programmed Death (PD)-1 inhibitor, is approved following prior VEGF inhibitor treatment. Other PD-1 and PD-ligand (L)-1 inhibitors are undergoing clinical development. Expert opinion: Combinations of inhibitors of the PD1/PD-L1 axis with VEGF inhibitors or cytotoxic T-lymphocyte antigen (CTLA)-4 inhibitors have shown promising efficacy in mRCC. The development of biomarkers predictive for benefit and rational tolerable combinations are both important pillars of research to improve outcomes in RCC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|